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Abstract
Background: This was a prespecified secondary analysis of a randomized trial that analyzed bone density and pain
response following fractionated intensity-modulated radiotherapy (IMRT) versus three-dimensional conformal
radiotherapy (3DCRT) for palliative management of spinal metastases.
Methods/materials: Sixty patients were enrolled in the single-institutional randomized exploratory trial, randomly
assigned to receive IMRT or 3DCRT (30 Gy in 10 fractions). Along with pain response (measured by the Visual
Analog Scale (VAS) and Chow criteria), quantitative bone density was evaluated at baseline, 3, and 6 months in
both irradiated and unirradiated spinal bodies, along with rates of pathologic fractures and vertebral compression
fractures.
Results: Relative to baseline, bone density increased at 3 and 6 months following IMRT by a median of 24.8% and
33.8%, respectively (p < 0.01 and p = 0.048). These figures in the 3DCRT cohort were 18.5% and 48.4%, respectively
(p < 0.01 for both). There were no statistical differences in bone density between IMRT and 3DCRT at 3 (p = 0.723)
or 6 months (p = 0.341). Subgroup analysis of osteolytic and osteoblastic metastases showed no differences
between groups; however, mixed metastases showed an increase in bone density over baseline in the IMRT (but
not 3DCRT) arm. The 3-month rate of the pathological fractures was 15.0% in the IMRT arm vs. 10.5% in the 3DCRT
arm. There were no differences in pathological fractures at 3 (p = 0.676) and 6 (p = 1.000) months. The IMRT arm
showed improved VAS scores at 3 (p = 0.037) but not 6 months (p = 0.430). Using Chow criteria, pain response was
similar at both 3 (p = 0.395) and 6 (p = 0.732) months.
Conclusions: This the first prospective investigation evaluating the impact of IMRT vs. 3DCRT on bone density.
Along with pain response and pathologic fracture rates, significant rises in bone density after 3 and 6 months were
similar in both cohorts. Future randomized investigations with larger sample sizes are recommended.
Trial registration: NCT, NCT02832830. Registered 14 July 2016
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Introduction
Spinal metastases, which occur in up to 40% of advanced-
stage cancer patients, can be a major source of symptom-
atic burden and quality of life detriment [1]. These include
not only pain and immobility, but also neurological deficits
and risk of pathological fractures. Historically, convention-
ally fractionated three-dimensional conformal radiotherapy
(3DCRT) has been the technique of choice to palliate these
cases [2, 3]. However, the advancement of technologies
such as intensity-modulated radiation therapy (IMRT) al-
lows for safer dose-escalation by means of higher con-
formality, image guidance, and decreased doses to nearby
organs-at-risk (OARs).
Because much of current research on spinal metastases
involves stereotactic radiotherapy (achieved in 5 or fewer
fractions), fractionated IMRT has remained an under-
studied option for these cases. Although stereotactic
radiotherapy may be accomplished by inverse-planned
IMRT, volumetric modulated arc therapy (VMAT), or
TomoTherapy techniques, fractionated IMRT (most com-
monly 30 Gy in 10 fractions as in this study), which can
also be performed with any of the aforementioned tech-
niques, has largely been overshadowed to date and thus
deserves further study.
There are known serious adverse events associated
with spinal irradiation, such as decreases in bone density
potentially resulting in vertebral compression fractures
(VCFs). There are no randomized data evaluating these
parameters in IMRT versus 3DCRT to date. This was a
prespecified secondary analysis of a randomized trial,
which evaluated bone density and pain response follow-
ing IMRT versus conventional 3DCRT as part of pallia-
tive management of painful spinal metastases.
Materials and methods
Trial design and participants
The randomized trial, registered on clinicaltrials.gov
(NCT02832830), was approved by the Heidelberg Uni-
versity Independent Ethics Committee (Nr. S-238/2016).
Details of the study design have been published previ-
ously [4]. The primary endpoint of this randomized,
single-institutional, pilot trial was 3-month RT-induced
toxicity following delivery of 30 Gy in 10 fractions of
image-guided IMRT versus conventional 3DCRT in pa-
tients with previously untreated spinal metastases. All
patients had an established indication for RT, including
pain and/or neurological deficits. The present study was
a prespecified secondary analysis of bone density, as well
as pain response and rates of pathologic fracture and
VCF.
A block randomization approach (block size of 6) was
used to ensure that the two groups were balanced. In
addition to the above, inclusion criteria were ages 18–85,
a Karnofsky performance score ≥ 50, and ability to provide
written informed consent. Exclusion criteria were subjects
with significant neurological or psychiatric disorders pre-
cluding informed consent, previous RT to the given irradi-
ation site, or multiple myeloma or lymphoma histology.
Number or location of metastases were not specific cri-
teria for inclusion or exclusion, nor was the presence of
spinal cord compression.
Assessment of endpoints
Per protocol, bone density in irradiated and non-irradiated
vertebral bodies, other pathologic vertebral fractures, and
VCFs were assessed at baseline and at 3 and 6 months
after RT. Bone density was assessed with the Syngo Osteo
CT workstation in manually selected regions of interest.
Hounsfield units (HU) were used for bone density mea-
surements. The Siemens Somatom Sensation Open (Sie-
mens, Erlangen, Germany) scanner was used for all CT
examinations. Measurements were carried out at the ap-
propriate site by a single physician in light of inter-
observer bias. During the observation period, because
most participants received anti-osteoresoptive treatment,
changes in bone density in unaffected vertebrae were also
measured.
Pathologic fractures were diagnosed by experienced ra-
diologists by means of CT and/or MRI imaging by com-
paring to baseline imaging tests. New fractures were, by
definition, not present on initial imaging, whereas pro-
gressive fractures referred to visibly increasing size and/
or number of fracture gaps, dislocation of fracture frag-
ments, or increasing sintering of the VCF. A VCF was
defined as the reduction of the vertebral body height by
more than 20%. Each of these was grouped under the
term of “pathologic fractures”.
In addition to evaluating neuropathic pain, overall pain
response to RT was quantified by the visual analog scale
(VAS), measured at the irradiated region prior to, imme-
diately following, and at 3 and 6 months after RT. Pain
response was designated as complete response (CR), par-
tial response (PR), pain progression (PP), and intermedi-
ate pain (IP) according to the International Bone
Consensus response categories by Chow et al. [5].
Complete response (CR) was defined as no pain (VAS =
0) after 3 months and partial response (PR) as an im-
provement by at least two points after 3 and 6 months.
CR referred to VAS = 0 with no concurrent increase in
analgesic intake (stable or reducing analgesics in daily
oral morphine equivalents). PR was pain reduction of 2
or more without increase in analgesics, or analgesic re-
duction of at least 25% from baseline without an in-
crease in pain. PP was defined as increase in pain score
of ≥2 above baseline with stable oral morphine equiva-
lents, or an increase of 25% or more in the latter with
the pain score stable or 1 point above baseline. Any re-
sponse not covered by the CR, PR or PP definitions was
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Table 1 Baseline characteristics of randomly assigned participants
IMRT group n = 30 3D group n = 30 p-value
n % n %
Age (years) 0.219
Mean (SD) 66,1 (10,5) 62,5 (11,8)
Karnofsky-Perfomance Status 0.283
Mean (SD) 64,9 (9,32) 61,3 (9,7)
Gender 0.795
Male 17 56,7 16 53,3
Female 13 43,3 14 46,7
Weight (kg, SD) 75,8 (14,9) 76,2 (19,4) 0.929
Height (cm, SD) 171,6 (8,8) 172,2 (8,6) 0.790
Body mass index (BMI) 0.960
Mean (SD) 25,7 (4,4) 25,6 (5,7)
Primary site
Lung cancer 11 36,7 16 53,3
ABreast cancer 7 23,3 6 20
Prostata cancer 6 20 1 3,3
Other 6 20 7 23,3
Volume of metastases at baseline
Mean size (mm3) 30 1166,6 30 0.191
Localization metastases 0.261
Cervical 4 13,3 5 16,7
Thoracic 15 50 15 50
Lumbar 11 36,7 7 23,3
Sacrum 0 0 3 10
Number metastases 0.140
1 metastase 17 56,7 10 33,3
2 metastases 4 13,3 9 30
3 metastases 9 30 11 36,7
Distant metastases at baseline
Viszeral 14 46,7 10 33,3 0.292
Lung 7 23,3 6 20 0.754
Brain 4 13,3 5 16,7 0.718
Tissue 5 16,7 5 16,7 1.000
Hormontherapy 12 40 6 20 0.091
Immuntherapy 4 13,3 5 16,7 0.718
Chemotherapy 14 46,7 20 66,7 0.118
Surgery 18 60 13 43,3 0.196
Neurological deficit at baseline 4 13,3 3 10 0.688
Bisphosphonate at baseline 13 43,3 7 23,3 0.100
Orthopedic corset at baseline 9 30 10 33,3 0.781
Medication at baseline
Sleeping medication 5 16,7 2 6,7 0.228
Psychiatric medication 9 30 6 20 0.371
Opiate 20 66,7 17 56,7 0.426
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called “stable pain”. Responders were defined as having
CR or PR, and non-responders as having PP or IP.
Exploratory analysis of overall survival (OS) was per-
formed and defined as the time from initial diagnosis
until death or censored at last contact.
Radiotherapy
CT simulation was performed with custom immobilization
using Aquaplast® (Aquaplast Corporation, Wyckoff, NJ,
USA) head masks for cervical spine cases and Wingstep/
Prostep® (Elekta, Stockholm, Sweden) devices for thoracol-
umbar cases. In addition to OARs (dose constraints for
which were per QUANTEC recommendations), the clin-
ical target volume (CTV) was delineated on the planning
CT and encompassed the affected vertebral body [6]. The
planning target volume (PTV) was an isotropic 1 cm ex-
pansion of the CTV and was to be covered by the 90% iso-
dose line. The prescription dose for both cohorts was
30 Gy in 10 fractions.
The IMRT group received image-guided (mega- or kilo-
voltage cone beam computed tomography) RT by means
of step-and-shoot IMRT, VMAT (Elekta Versa HD accel-
erator), or helical TomoTherapy (Accuray Inc., Madison,
WI). The 3DCRT cohort was most commonly delivered
with two or three anteroposterior 6 MV individually-
formed beams. Position verification was applied by weekly
kilo-voltage CT and before each fraction by comparing or-
thogonal portal images with digitally reconstructed radio-
graphs from the planning CT.
Statistical analysis
Complete details regarding statistical analysis are pre-
sented elsewhere [4]. Owing to the exploratory nature of
this study, a complete power calculation was not pos-
sible; however, with 30 patients in each group, it was
possible to detect a standardized mean-value effect of
0.8 with 80% power at a significance level of 0.05.
All variables were analyzed descriptively by tabulation
of the measures of the empirical distributions. According
to the scale level of the variables, means (Hodges-Leh-
mann estimates) and standard deviations or absolute
and relative frequencies, respectively, were reported.
Additionally, for variables with longitudinal measure-
ments, the time courses of individual patients and sum-
marized by treatment groups. Descriptive p-values of the
corresponding statistical tests comparing the treatment
groups were given. Analysis of covariance (ANOVA)
with repeated measurements, with treatment group as a
Table 1 Baseline characteristics of randomly assigned participants (Continued)
IMRT group n = 30 3D group n = 30 p-value
n % n %
NSAID 23 76,7 19 63,3 0.260
Explanation: Others: carcinoma of unknown primary (CUP), gastrointestinal stromal tumor (GIST), melanoma, mesothelioma, pancreatic cancer, renal cancer.
Abbreviations: NSAID nonsteroidal inflammatory drug
Fig. 1 Consort diagram of the trial
Sprave et al. Radiation Oncology          (2018) 13:212 Page 4 of 10
factor, and pain medication as covariates, were done.
The Wilcoxon rank-sum test was used to detect possible
differences between groups after 3 and 6 months. All
statistical analyses were done using SAS software Ver-
sion 9.4 or higher (SAS Institute, Cary, NC, USA).
Funding source
The sponsors of the study had no role in study design,
data analysis, data interpretation and wording of the re-
port. The corresponding author (HR) had full access to
the entire data of the study and had final responsibility
regarding the decision to submit for publication.
Results
From November 2016 to May 2017, 60 patients were ran-
domized. No patients were excluded post randomization.
Baseline characteristics were balanced between the two
treatment arms (Table 1, as previously reported) [7].
Although all surviving patients completed all assess-
ments, not all patients survived by the three and six
month time periods. Within the first 3 months, 10 patients
Fig. 2 Overall survival of both arms
Table 2 Bone density of both groups in metastatic bone before RT (baseline), as well as 3 and 6 months after RT
IMRT group Within group 3DCRT group Within group Differences between groups
n Median SD p-value n Median SD p-value HL 95% CI p-value
All metastases
HU
Baseline
30 258.5 183.3 30 195.0 125.4 62 5.0–126.0 0.037
HU T2 20 419.3 232.7 19 300.0 165.7 −59.5 −194.0-59.0 0.232
HU T3 18 416.8 277.7 12 454.0 185.4 61.5 − 146.0-229 0.641
3 months
HU T0-T2 20 90.5 134.2 < 0.01 19 35.0 87.1 < 0.01 −25.0 − 86.0-42.0 0.407
HU T0-T2 (%) 20 24.8 51.0 < 0.01 19 18.5 38.7 < 0.01 −4.5 −25.5-21.9 0.723
6 months
HU T0-T3 18 124.0 166.0 0.023 12 132.0 157.7 < 0.01 59.0 −73.0-193.0 0.330
HU T0-T3 (%) 18 33.8 61.6 0.048 12 48.4 70.7 < 0.01 34.0 −20.3-91.1 0.341
The results were presented by absolute and relative values (%) of HU within and between groups as median (Hodges–Lehmann estimate) and IQR
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Table 3 The subgroup analysis of the bone density (HU = Hounsfield units) in metastatic bone before RT (baseline), as well as 3 and
6 months after RT
IMRT group 3DCRT group Differences between groups
n Median SD n Median SD HL 95% CI p-value
Mixed
HU Baseline 17 242.0 100.1 10 230.5 77.3 −41.5 − 128.0-40.0 0.238
HU T2 11 360.0 153.1 5 418.0 89.4 58.0 − 114-204.0 0.450
HU T3 9 355.0 174.1 4 559.5 132.0 190.5 −61.0-416.0 0.190
3 months
HU T0-T2 11 102.0 92.2 5 164.0 68.4 59.0 −43.0-174.0 0.213
HU T0-T2 (%) 11 38.8 41.2 5 60.8 48.5 25.7 −32.5-89.5 0.256
6 months
HU T0-T3 9 176.0 123.1 4 301.0 89.4 161.5 73.0–341.0 0.025
HU T0-T3 (%) 9 55.0 61.1 4 145.9 42.2 80.7 8.7–155.1 0.037
Osteolytic
HU Baseline 6 178.5 74.3 14 156.5 60.9 20.0 −60.0 − 82.0 0.536
HU T2 4 269.5 198.4 8 181.5 70.8 84.0 -82.0-387.0 0.270
HU T3 4 153.0 127.7 3 295.0 82.8 126.5 − 184.0-277.0 0.377
3 months
HU T0-T2 4 35.5 171.2 8 16.0 38.0 19.5 −53.0-364.0 0.489
HU T0-T2 (%) 4 20.3 83.11 8 9.3 21.2 12.2 −27.5-178.4 0.489
6 months
HU T0-T3 4 10.0 95.3 3 64.0 89.1 110.0 −60.0-315.0 0.212
HU T0-T3 (%) 4 −0.8 55.4 3 27.7 55.0 46.9 −61.2-174.2 0.377
Osteoblastic
HU Baseline 7 419.0 247.6 6 426.0 159.8 −94.5 − 415.0-172.0 0.520
HU T2 5 574.0 327.0 6 481.5 174.4 145.5 − 284.0-604.0 0.411
HU T3 5 700.0 374.8 5 475.0 196.4 255.0 − 367.0-711.0 0.296
3 months
HU T0-T2 5 52.0 188.3 6 13.0 103.3 45.0 − 311.0-155.0 0.647
HU T0-T2 (%) 5 15.4 35.8 6 3.1 27.5 3.0 −57.0-30.8 1.000
6 months
HU T0-T3 5 130.0 241.7 5 57.0 102.9 42.0 − 408.0-224.0 0.676
HU T0-T3 (%) 5 15.4 47.2 5 13.6 27.3 1.7 −77.9-53.4 1.000
The results were presented by absolute and relative values (%) of HU within and between groups as median (Hodges–Lehmann estimate) and IQR. Abbreviations:
HU Hounsfield units, IQR interquartile range, T0 baseline, T2 3 months, T3 6 months, T0–T2 difference in baseline minus 3 months, T0-T3 difference in baseline
minus 6 months
Table 4 Results of pathological fractures of both groups
IMRT group 3DCRT group Differences between groups
n n/(%) n n/(%) p-value
No Yes No Yes
Baseline 30 29 (96.7%) 1 (3.3%) 30 26 (86.7%) 4 (13.3%) 0.161
3 months 20 17 (85.0%) 3 (15%) 19 17 (89.5%) 2 (10.5%) 0.676
6 months 18 15 (83.3%) 3 (16.7%) 12 10 (83.3%) 2 (16.7%) 1.000
Abbreviations: n = alive participants; n/% = total number of pathological fractures in absolute and percentage terms
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(33.3%) in the IMRT group had died, along with 11 pa-
tients (36.7%) in the 3DCRTarm. Between 3 and 6 months,
another 2 patients (10%) died from tumor progression in
the IMRT cohort, along with a further 7 patients (36.8%)
in the 3DCRT arm (Fig. 1). OS did not differ between
groups (p = 0.187) (Fig. 2). The mean follow-up was
6.3 months (IQR 2.5–9.3) for both groups.
As compared to baseline, bone density became signifi-
cantly higher at 3 and 6 months following IMRT by a
median percentage of 24.8% and 33.8% (p < 0.01 for
3 months and p = 0.048 for 6 months), respectively
(Table 2). These figures in the 3DCRT cohort were 18.5%
and 48.4% (p < 0.01 for both), respectively. There were no
statistical differences in bone density between IMRT and
3DCRT at 3 (p = 0.723) or 6 months (p = 0.341).
Subgroup evaluation of solely osteolytic lesions at 3
and 6 months showed no significant differences between
groups (p = 0.489 and p = 0.377 respectively) (Table 3).
There were no differences between bone density changes
in osteoblastic metastases in the IMRT and 3DCRT
groups at 3 or 6 months (p = 1.000 for both) (Table 3).
Subgroup evaluation of mixed lesions showed a signifi-
cant difference (p = 0.037) at 6 months but not at
3 months (p = 0.256) (Table 3).
Bone density in unaffected vertebrae did not show
substantial changes within groups at 3 and 6 months fol-
lowing RT (IMRT: p = 0.623 and p = 0.167, 3DCRT: p =
0.934 and p = 0.147). There were also no significant dif-
ferences between the IMRT and 3DCRT arms at 3 (p =
0.574) or 6 months (p = 0.949).
Preexisting pathological fractures existed in 3.3% pa-
tients in the IMRT arm vs. 13.3% in the 3DCRT group
(p = 0.161) (Table 4). By 3 and 6 months, these numbers
rose to 15.0% vs. 10.5% (p = 0.676) and 16.7% vs. 16.7%
(p = 1.000), respectively. No pathological fractures in ei-
ther group required salvage surgical intervention.
Pain assessment, using VAS scoring, was similar between
cohorts at baseline (p = 0.882) and immediately following
RT (p = 0.075). Although the IMRT arm showed improved
pain response at 3 months (p = 0.037), this was not ob-
served at 6 months (p = 0.430). There were also no differ-
ences in neuropathic pain at 3 (p = 0.946) or 6 (p = 0.661)
months. Using Chow criteria, pain response was statisti-
cally similar at both 3 (p = 0.395) and 6 (p = 0.732) months
(Table 5). At 3 months, 70.0% of patients that underwent
IMRT were categorized as responders, as compared to
47.4% in the 3DCRT arm (p = 0.151); these numbers at
6 months were 70.8% and 58.3%, respectively (p = 0.494).
There were no differences in the pattern of recorded
OMED consumption between groups at both 3 and
6 months after RT (Fig. 3).
Discussion
This prespecified secondary evaluation of a prospective
randomized trial is the first to investigate the impact of
image-guided IMRT on bone density as compared to
3DCRT. No differential effects on bone density or other
secondary endpoints were expected between IMRT and
3DCRT techniques at the time of study creation. The
significant rises in bone density after 3 and 6 months,
along with pathologic fracture rates and pain response,
were similar in both cohorts.
Despite rightful concerns regarding its cost-effectiveness
for palliative vertebral irradiation, IMRT is an attractive
option in part owing to the ability to perform simultan-
eous integrated boosting (SIB). This refers to allowing
multiple target volumes to receive different doses per frac-
tion, while maintaining the same total number of frac-
tions. Although no patient in this trial received SIB, this
topic will be better understood following maturation of
the IRON-2 trial, which consists of four arms: 20 Gy in 5
fractions (with or without SIB to 30 Gy in 5 fractions) and
30 Gy in 10 fractions (with or without SIB to 40 Gy in 10
fractions) [8]. Evaluating bone density in such instances
will be essential to evaluate whether higher fractional
doses are safe from the bone density standpoint as well.
From these data, it was noteworthy that baseline bone
density was higher in the IMRT arm (p = 0.037). Al-
though numerically higher at 3 months as well (median
419 versus 300), this did not reach statistical significance
(p = 0.232), likely owing to the lower sample sizes avail-
able at 3 months. Nevertheless, 6 month values were nu-
merically comparable. Moreover, the relative magnitude
of bone density change at 3 and 6 months was also
Table 5 Response according to Brief Pain Inventory score at 3
and 6 months in the per-protocol cohort
IMRT group n = 20 3DCRT group n = 19
After 3 months n % n % p-value
CR 10 50 5 26,3 0.395
PR 4 20 4 20,1
PP 1 5 3 15,8
IP 5 25 7 36,8
Responders 14 70 9 47,4 0.151
Non-responders 6 30 10 52,6
IMRT group n = 17 3DCRT group n = 12
After 6 months
CR 7 41,2 3 25 0.732
PR 5 29,4 4 33,3
PP 2 11,8 3 25
IP 3 17,7 2 16,7
Responders 12 70,8 7 58,3 0.494
Non-responders 5 29,4 5 41,7
Abbreviations: CR complete response, PR partial response, PP pain progression,
IP intermediate pain
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numerically and statistically comparable between both
groups. This implies that components of bone density
changes specifically related to RT are likely similar be-
tween both cohorts.
What is less clear are the findings related to mixed
osteolytic-osteoblastic lesions at 6 months. The three-
month values were not significantly different between
cohorts, nor were those for purely osteolytic or osteo-
blastic metastases. As such, these analyses with clearly
small sample sizes may not provide robust conclusions in
this subgroup of patients. Additionally, only a few previ-
ous studies included mixed or osteoblastic metastases. In
contrast to our results, Eggermont et al. did not observe
any bone density changes in mixed proximal femur lesions
after 4 and 10 weeks [9]. This could possibly result from
an earlier date of collection and lower doses (prescription
up to 20 or 24 Gy). In line with these results, less
remineralization in the extremities was reported by Rieden
and coauthors [10].
Wachenfeld et al. reported an increase in CT density
in osteolytic metastases to approximately 150% of the
initial value at 3 months after multi-fraction irradiation
[11]. Koswig and Budach showed improvement of bone
density in osteolytic metastases by 173% at 6 months
Fig. 3 OMED and VAS of both groups at measured points
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after multi-fraction irradiation [12]. In this trial, how-
ever, the differences were 20.3% and 9.3% in the IMRT
and 3DCRT arms, respectively, at 3 months; 6-month
values were − 0.8% and 27.7%, respectively. There are
several causes of these discrepancies, including the spe-
cific patient population, histology, size of metastases and
several other factors.
The improved pain response based on VAS in the IMRT
group (p = 0.037) at 3 months could have been from a
greater use of hormonal therapy in metastatic prostate
carcinoma. That being said, potential imbalances in anti-
osteoresorptive therapies are an unlikely cause of the find-
ings herein, as densities of unaffected vertebrae yielded no
differences between groups. Rief et al. studied the impact
of resistance training concomitantly with conventional
multi-fraction 3DCRT on bone density in a randomized
controlled study and found no significant differences in
the uninvolved spine [13]. Therefore, it has been sug-
gested that bisphosphonates may not exert decisive effects
in this circumstance.
Despite the randomized design and standardized evalu-
ation of bone density and recording of all pathological
structures, several limitations must be noted. In addition
to the lower sample size and shorter follow-up, robust
conclusions based on statistical comparisons cannot be
made, as partially discussed above. Second, a possible
methodological weakness in our study was the lack of a
control group. Third, many patients did not receive con-
current radiotherapy and chemotherapy, so the relation-
ship of systemic therapy on bone density changes cannot
be entirely excluded [14–18]. Fourth, some participants
received immunotherapy and prior or subsequent radio-
therapy to other distant metastases. The abscopal effect in
this setting has been sporadically described but not suffi-
ciently clarified [19, 20], but our study did not investigate
this causality. Fifth, few studies can entirely account for
other factors influencing bone density such as diet, par-
ticular medications, or vitamin supplementation. There
may also be heterogeneity in this population given the
specific location of vertebral metastases (e.g. vertebral
body versus lamina/pedicle) as well as degree of soft tissue
extension. Although these may limit applicability to other
studies, larger randomized data are recommended to val-
idate these results.
Conclusions
This prespecified secondary evaluation of a prospective
randomized trial is the first to investigate the impact
of image-guided IMRT on bone density as compared
to 3DCRT. The significant rises in bone density after 3
and 6 months, along with pain response and patho-
logic fracture rates, were similar in both cohorts. Fu-
ture randomized investigations with larger sample
sizes are recommended.
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